{
    "clinical_study": {
        "@rank": "53661", 
        "arm_group": [
            {
                "arm_group_label": "VT-1161 (oral)", 
                "arm_group_type": "Experimental", 
                "description": "VT-1161 300 mg q.d. for 3 days"
            }, 
            {
                "arm_group_label": "Fluconazole", 
                "arm_group_type": "Active Comparator", 
                "description": "Fluconazole 150 mg administered orally in a single dose (administered blinded to match the VT-1161 dose regimens)"
            }
        ], 
        "brief_summary": {
            "textblock": "CYP51 is an enzyme essential for fungal growth.  Inhibition of CYP51 results in the\n      accumulation of compounds toxic to the fungus.  CYP51 is the target of the class of drugs\n      referred to as 'azole antifungals'.  The lack of selectivity by the azole antifungals is\n      responsible for many of the side effects associated with these drugs.  VT-1161 has been\n      design to be safer and more active against the fungal species typically responsible for\n      vaginal yeast infections (i.e. vulvovaginal candidiasis)"
        }, 
        "brief_title": "A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Acute Vaginal Candidiasis (Yeast Infection)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Candidiasis, Vulvovaginal", 
        "condition_browse": {
            "mesh_term": [
                "Candidiasis", 
                "Candidiasis, Vulvovaginal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Females \u226518 and <65 years\n\n          -  Clinical diagnosis of symptomatic acute VVC\n\n          -  Positive KOH .At least one vulvovaginal sign (vulvovaginal erythema, edema, or\n             excoriation).\n\n          -  At least one vulvovaginal symptom (vulvovaginal itching, burning, or irritation)\n\n          -  A minimum composite vulvovaginal signs and symptoms score of \u22656\n\n          -  must be be able to swallow capsules\n\n        Exclusion Criteria:\n\n          -  Evidence of major organ system disease\n\n          -  History of cervical cancer\n\n          -  History of diabetes mellitus\n\n          -  Pregnant\n\n          -  Recent use of systemic antifungal drugs or systemic antimicrobial therapy for any\n             reason\n\n          -  Recent use of drugs to treat vaginal infections\n\n          -  Recent use of immunosuppressive therapies"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01891331", 
            "org_study_id": "VMT-VT-1161-CL-004"
        }, 
        "intervention": [
            {
                "arm_group_label": "VT-1161 (oral)", 
                "intervention_name": "VT-1161 (oral)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fluconazole", 
                "intervention_name": "Fluconazole (oral)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fluconazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lake Worth", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33461"
                    }, 
                    "name": "Altus Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33161"
                    }, 
                    "name": "Healthcare Clinical Data, Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11203"
                    }, 
                    "name": "SUNY Downstate Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27607"
                    }, 
                    "name": "Lyndhurst Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27103"
                    }, 
                    "name": "Lyndhurst Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19102"
                    }, 
                    "name": "Drexel Vaginitis Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Irving", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75062"
                    }, 
                    "name": "Brownstone Clinical Trials, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Harborview ID Research Clinic"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2a, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Vulvovaginal signs and symptoms will be evaluated at screening/baseline and at test of cure day 28 (Week 4)", 
                "measure": "To evaluate the composite clinical efficacy of oral VT-1161 compared with fluconazole in the treatment of patients with moderate to severe acute vulvovaginal candidiasis", 
                "safety_issue": "No", 
                "time_frame": "Test of Cure conducted at baseline (day 1)"
            }, 
            {
                "description": "Clinical efficacy will be evaluated at screening/baseline (Day 1) and at test-of-cure visit Week 4 (Day 28)", 
                "measure": "To evaluate the composite clinical efficacy of oral VT-1161 compared with oral fluconazole in the treatment of patients with moderate to severe acute vulvovaginal candidiasis", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01891331"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Viamet Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Viamet Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}